Safety of BNT162b2 mRNA vaccine booster in the setting of Ad26.COV2.S-associated VITT.
Saved in:
| Title: | Safety of BNT162b2 mRNA vaccine booster in the setting of Ad26.COV2.S-associated VITT. |
|---|---|
| Authors: | Abou-Ismail MY; Division of Hematology and Hematologic Malignancies, Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, UT., Kanack AJ; Division of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN., Splinter NP; Division of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN., Smock KJ; Department of Pathology, University of Utah Health Sciences Center, Salt Lake City, UT.; Associated Regional and University Pathologists Institute for Clinical and Experimental Pathology®, Salt Lake City, UT; and., Moser KA; Department of Pathology, University of Utah Health Sciences Center, Salt Lake City, UT.; Associated Regional and University Pathologists Institute for Clinical and Experimental Pathology®, Salt Lake City, UT; and., Padmanabhan A; Divisions of Hematopathology, Transfusion Medicine, & Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN. |
| Source: | Blood advances [Blood Adv] 2022 Sep 27; Vol. 6 (18), pp. 5327-5329. |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
